

# Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exception Review

Summary and Goals .....	2
Background .....	2
Recommendation.....	3
Ascites .....	3
Budd Chiari.....	4
Gastrointestinal Bleeding.....	4
Hepatic Encephalopathy .....	5
Hepatic Epithelioid Hemangioendothelioma.....	5
Hepatic Hydrothorax.....	5
Hereditary Hemorrhagic Telangiectasia .....	6
Multiple Hepatic Adenomas .....	7
Neuroendocrine Tumors (NET) .....	7
Polycystic Liver Disease (PLD) .....	8
Portopulmonary Hypertension .....	9
Primary Sclerosing Cholangitis or Secondary Sclerosing Cholangitis.....	9
Metabolic Disease.....	9
Post-Transplant Complications .....	10
Small for Size Syndrome.....	10
Chronic Rejection.....	10
Diffuse Ischemic Cholangiopathy.....	10
Late Vascular Complications .....	11
Pruritus.....	11
Conclusion.....	12

## Summary and Goals

For many patients with chronic liver disease the risk of death without access to liver transplant can be accurately predicted by the MELD score, which is used to prioritize candidates on the waiting list. However, for some patients the need for liver transplant is not based on the degree of liver dysfunction due to the underlying liver disease but rather a complication of the liver disease. These complications have an increased risk of mortality or waitlist dropout without access to timely transplant and are not reflected in the calculated MELD score.<sup>1</sup> This document summarizes available evidence to assist clinical reviewers in approving candidates for MELD exceptions. It contains guidance for specific clinical situations for use by the Review Board to evaluate common exceptional case requests for adult candidates with the following diagnoses, not all of which are appropriate for MELD exception:

- Ascites
- Budd Chiari
- GI Bleeding
- Hepatic Encephalopathy
- Hepatic Epithelioid Hemangioendothelioma
- Hepatic Hydrothorax
- Hereditary Hemorrhagic Telangiectasia
- Multiple Hepatic Adenomas
- Neuroendocrine Tumors (NET)
- Polycystic Liver Disease (PLD)
- Portopulmonary Hypertension
- Primary Sclerosing Cholangitis (PSC) or Secondary Sclerosing Cholangitis (SSC)
- Metabolic Disease
- Post-Transplant Complications, including Small for Size Syndrome, Chronic Rejection, Diffuse Ischemic Cholangiopathy, and Late Vascular Complications
- Pruritus

These guidelines are intended to promote consistent review of these diagnoses and summarize the Committee's recommendations to the OPTN Board of Directors.

This resource is not OPTN Policy, so it does not carry the monitoring or enforcement implications of policy. It is not an official guideline for clinical practice, nor is it intended to be clinically prescriptive or to define a standard of care. This resource is intended to provide guidance to transplant programs and the Review Board.

## Background

A liver candidate receives a MELD<sup>2</sup> or, if less than 12 years old, a PELD<sup>3</sup> score that is used for liver allocation. The score is intended to reflect the candidate's disease severity, or the risk of 3-month mortality without access to liver transplant. When the calculated score does not reflect the candidate's medical urgency, a liver transplant program may request an exception score. A candidate that meets the

---

<sup>1</sup> Waitlist dropout is removal from the waiting list due to the candidate being too sick to transplant.

<sup>2</sup> Model for End-Stage Liver Disease

<sup>3</sup> Pediatric End-Stage Liver Disease

criteria for one of nine diagnoses in policy is approved for a standardized MELD exception.<sup>4</sup> If the candidate does not meet criteria for standardized exception, the request is considered by the Review Board.

The OPTN Liver and Intestinal Organ Transplantation Committee (hereafter, “the Committee”) has developed guidance for adult MELD exception candidates. The MELD Exceptions and Enhancements Subcommittee proposed these recommendations after reviewing the 2006 MELD Exception Study Group (MESSAGE) Conference, a descriptive analysis of recent MELD exception requests submitted to the OPTN, and available peer-reviewed literature. To support a recommendation for approving additional MELD exception points, there must have been adequate evidence of increased risk of mortality associated with the complication of liver disease.

This guidance replaces any independent criteria that OPTN regions used to request and approve exceptions, commonly referred to as “regional agreements.” Review Board members and transplant centers should consult this resource when considering MELD exception requests for adult candidates with the following diagnoses.

## Recommendation

### Ascites

**There is inadequate evidence to support granting a MELD exception for ascites in adult candidates with the typical clinical symptoms associated with this diagnosis.**

Ascites is a common clinical finding in liver transplant candidates. Refractory ascites, as defined by the International Ascites Club, occurs in 5-10% of patients with portal hypertension and has a 1-year mortality rate of approximately 50%.<sup>5,6,7,8</sup> Hyponatremia is common in patients with cirrhosis and refractory ascites from portal hypertension.<sup>9,10,11</sup> In January 2016, the OPTN implemented a modification to the MELD score to incorporate serum sodium for candidates with a calculated MELD greater than 11.<sup>12</sup> Much of the excess mortality risk related to ascites is similar to portal hypertension and hepatorenal syndrome and will be accurately reflected in the lab values used to calculate the MELD score, specifically the serum creatinine and serum sodium. Therefore, MELD exception for ascites is not recommended.

---

<sup>4</sup>Policy 9.3.C: Specific MELD/PELD Exceptions, Organ Procurement and Transplantation Network Policies.

<sup>5</sup>Moore, K.P., F. Wong, P. Gines, et al. “The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.” *Hepatology* 38 (2003): 258-66.

<sup>6</sup>Runyon, B.A., AASLD. “Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.” *Hepatology* 57 (2013): 1651-3.

<sup>7</sup>Runyon, B.A., Committee APG. “Management of adult patients with ascites due to cirrhosis: an update.” *Hepatology* 49 (2009): 2087-107.

<sup>8</sup>Gines P., A. Cardenas, V. Arroyo, et al. “Management of cirrhosis and ascites.” *N Engl J Med* 350 (2004):1646-54.

<sup>9</sup>Biggins, S.W., W.R. Kim, N.A. Terrault, et al. “Evidence-based incorporation of serum sodium concentration into MELD.” *Gastroenterology* 130 (2006):1652-60.

<sup>10</sup>Porcel, A., F. Diaz, P. Rendon, et al. “Dilutional hyponatremia in patients with cirrhosis and ascites.” *Arch Intern Med* 162 (2002):323-8.

<sup>11</sup>Gines, A., A. Escorsell, P. Gines, et al. “Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.” *Gastroenterology* 105 (1993):229-36.

<sup>12</sup>Biggins, S.W. “Use of serum sodium for liver transplant graft allocation: a decade in the making, now is it ready for primetime?” *Liver Transpl* 21 (2015):279-81.

## Budd Chiari

**Approval of MELD exception points for adult candidates with Budd Chiari may be appropriate in some instances.**

Budd Chiari syndrome is an uncommon manifestation of hepatic vein thrombosis and patients might present with evidence of decompensated portal hypertension (ascites and hepatic hydrothorax) among others.<sup>13</sup> Medical management may include diuresis and anticoagulation; or more aggressive management with Transjugular Intrahepatic Portosystemic Shunt (TIPS), portosystemic shunting, or liver transplant.<sup>14</sup> Anticoagulation and pharmacologic management is the cornerstone treatment.<sup>15,16</sup> Patients with severe portal hypertension not controlled with the standard of care might have evidence of hyponatremia or renal impairment, but these will be accurately reflected by the calculated MELD score.

Liver transplant candidates with Budd Chiari syndrome could be considered on an individual basis for a MELD exception based on severity of liver dysfunction and failure of standard management.

Documentation submitted for case review should include all of the following:

- Failed medical management (please specify)
- Etiology of hypercoagulable state
- Any contraindications to TIPS or TIPS failure; specify specific contraindication
- Decompensated portal hypertension in the form of hepatic hydrothorax requiring thoracentesis more than 1 liter per week for at least 4 weeks (transudate, no evidence of empyema, and negative cytology or any evidence of infection).
- Documentation that extrahepatic malignancy has been ruled out

## Gastrointestinal Bleeding

**There is inadequate evidence to support granting a specific MELD exception for gastrointestinal bleeding in adult candidates who experience acute or chronic blood loss independent of their calculated MELD.**

There is also inadequate evidence to support a MELD exception for transfusion dependence independent of MELD with one exception, spur cell hemolytic anemia (SCHA).<sup>17</sup> However, due to the infrequent occurrence of SCHA in a transplant candidate, and its common association with recent alcohol use or active infection, MELD exception is not recommended. Similarly there is no evidence to support that candidates with transfusion dependence who develop antibodies while waiting warrant a MELD exception.<sup>18,19</sup>

---

<sup>13</sup>Janssen, H.L., J.C. Garcia-Pagan, E. Elias, et al. "Budd-Chiari syndrome: a review by an expert panel." *Hepatology* 38 (2003): 364-371.

<sup>14</sup>Seijo, S., A. Plessier, J. Hoekstra, et al. "Good long-term outcome of Budd-Chiari syndrome with a step-wise management." *Hepatology* 57 (2013): 571962-8.

<sup>15</sup>Plessier, A., A. Sibert, Y. Consigny, et al. "Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome." *Hepatology* 44 (2006):1308-16.

<sup>16</sup>DeLeve, L.D., D.C. Valla, G. Garcia-Tsao. "Vascular disorders of the liver AASLD practice guidelines." *Hepatology* 49 (2009): 1729-64.

<sup>17</sup>Alexopoulou, A., L. Vasilieva, T. Kanellopoulou, et al. "Presence of spur cells as a highly predictive factor of mortality in patients with cirrhosis." *J Gastroenterol Hepatol.* 4 (2014):830-4.

<sup>18</sup>Lyles, T., A. Elliott, D.C. Rockey. "A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding." *J Clin Gastroenterol* 48 (2014):712-20.

<sup>19</sup>Flores-Rendón, A.R., J.A. González-González, D. García-Compean, et al. "Model for end stage of liver disease (MELD) is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding." *Ann Hepatol* 7 (2008):230-4.

## Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a complication of chronic liver with an associated mortality independent of MELD scoring. Presently, no additional MELD priority for HE is recommended in the absence of a widely available, reliable, objective assessment of its severity.<sup>20, 21,22,23</sup>

## Hepatic Epithelioid Hemangioendothelioma

### **Approval of MELD exception points for adult candidates with unresectable Hepatic Epithelioid Hemangioendothelioma (HEHE) may be appropriate in some instances.**

Biopsy must be performed to establish the diagnosis of HEHE, and exclude hemangiosarcoma. HEHE is a rare, low grade primary liver tumor of mesenchymal cell origin. Because of the rarity of the diagnosis, as well as the variability in presentation, the optimal treatment strategies are not fully established. However, for lesions which cannot be resected, liver transplant is associated with 1, 5, and 10-year patient survival rates of 97%, 83%, and 74%; with more favorable results occurring in patients without microvascular invasion. The presence of extra-hepatic disease has not been associated with decreased survival post liver transplant and therefore should not be an absolute contraindication. Controversy regarding the role of liver transplant in treating HEHE relates to the variable course of disease in the absence of liver transplant, with some patients demonstrating regression or stabilization of disease and prolonged survival.<sup>24,25</sup>

## Hepatic Hydrothorax

### **There is inadequate evidence to support granting a MELD exception for hepatic hydrothorax in adult candidates with the typical clinical symptoms associated with this diagnosis. Liver transplant candidates with chronic, recurrent, confirmed hepatic hydrothorax could be considered on individual basis for a non-standard MELD exception.**

Hepatic hydrothorax is a relatively uncommon complication of endstage liver disease occurring in only 5-10% of patients with cirrhosis and portal hypertension.<sup>26,27,28</sup> Hepatic hydrothorax can occur in either or both pleural spaces and can occur with or without portal hypertensive ascites.<sup>29</sup> By definition, hepatic hydrothorax is a transudative pleural effusion due to portal hypertension without a cardiopulmonary

---

<sup>20</sup> Kerbert, Annarein J., Enric Reverter, Lara Verbruggen, Madelon Tieleman, Miguel Navasa, Bart J. Mertens, Sergio Rodríguez-Tajes, et al. "Impact of Hepatic Encephalopathy on Liver Transplant Waiting List Mortality in Regions with Different Transplantation Rates." *Clinical Transplantation* 32, no. 11 (2018). <https://doi.org/10.1111/ctr.13412>.

<sup>21</sup> Chiranjeevi Gadiparthi et al., "Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy," *Digestive Diseases and Sciences* 63, no. 6 (February 2018): pp. 1647-1653, <https://doi.org/10.1007/s10620-018-5032-5>.

<sup>22</sup> Cristina Lucidi et al., "Hepatic Encephalopathy Expands the Predictivity of Model for End-Stage Liver Disease in Liver Transplant Setting: Evidence by Means of 2 Independent Cohorts," *Liver Transplantation* 22, no. 10 (2016): pp. 1333-1342, <https://doi.org/10.1002/lt.24517>.

<sup>23</sup> Robert J. Wong, Robert G. Gish, and Aijaz Ahmed, "Hepatic Encephalopathy Is Associated with Significantly Increased Mortality among Patients Awaiting Liver Transplantation," *Liver Transplantation*, 2014, <https://doi.org/10.1002/lt.23981>.

<sup>24</sup> Lerut, J.P., G. Orlando, R. Adam, et al. "The place of liver transplantation in the treatment of hepatic epithelioid hemangioendothelioma: report of the European liver transplant registry." *Ann Surg* 246 (2007): 949-57.

<sup>25</sup> Nudo, C.G., E.M. Yoshida, V.G. Bain, et al. "Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience." *Can J Gastroenterol* 22 (2008):821-4.

<sup>26</sup> Norvell, J.P., J.R. Spivey. "Hepatic hydrothorax." *Clin Liver Dis* 18 (2014): 439-49.

<sup>27</sup> Baikati, K., D.L. Le, I.I. Jabbour, et al. "Hepatic hydrothorax." *Am J Ther* 21 (2014): 43-51.

<sup>28</sup> Cardenas, A., T. Kelleher, S. Chopra. "Review article: hepatic hydrothorax." *Aliment Pharmacol Ther* 20 (2004): 271-9.

<sup>29</sup> Badillo, R., D.C. Rockey. "Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature." *Medicine (Baltimore)* 93 (2014): 135-42.

source. Infectious and malignant pleural effusions must be excluded. In this context, a serum pleural fluid albumin gradient (SPAG) of at least 1.1 g/dL may be more accurate in identifying hepatic hydrothorax than the more traditional Light's criteria for a transudative pleural effusion.<sup>22,30</sup> The mostly like explanation for hepatic hydrothorax is passage of fluid from the peritoneal space to the pleural space through diaphragmatic defects which can be documented by intraperitoneal injection of 99mTc-tagged nanocolloids followed by scintigraphy.<sup>31</sup> Unlike ascites, relatively small amounts of fluid in the pleural space (1 to 2 L) lead to severe symptoms such as shortness of breath and hypoxia. Initial management with dietary sodium restriction, diuretics, intravenous albumin, and therapeutic thoracentesis can be successful. Hepatic hydrothorax can be complicated by spontaneous bacterial empyema or iatrogenic complication of thoracentesis (infections, pneumothorax, or hemothorax). For chronic, recurrent, confirmed hepatic hydrothorax, transjugular intrahepatic portosystemic shunt, indwelling pleural catheter, and surgical repair of diaphragmatic defects can be effective in some patients yet risk additional complications. Like ascites, hepatic hydrothorax is similar to portal hypertension and hepatorenal syndrome and will be accurately reflected in the lab values used to calculate the MELD score, specifically the serum creatinine and serum sodium. Therefore, MELD exception for hepatic hydrothorax is not recommended in the majority of circumstances. Adult liver transplant candidates with chronic, recurrent, confirmed hepatic hydrothorax could be considered on an individual basis for a MELD exception provided that infectious and malignant causes have been ruled out. Documentation submitted for case review should include the following:

- At least 1 thoracentesis over 1 L weekly in last 4 weeks; report date and volume of each thoracentesis
- Pleural fluid is transudative by pleural albumin-serum albumin gradient of at least 1.1 and by cell count
- No evidence of heart failure; provide objective evidence excluding heart failure
- Pleural fluid culture negative on 2 separate occasions
- Pleural fluid cytology is benign on 2 separate occasions
- There is no contraindications to TIPS; specify specific contraindication
- Diuretic refractory

## Hereditary Hemorrhagic Telangiectasia

**Approval of MELD exception points for adult candidates with high output cardiac failure due to multiple arteriovenous (AV) malformations may be appropriate in some instances.** Hereditary hemorrhagic telangiectasia is an uncommon, autosomal dominant genetic disorder characterized by mucocutaneous telangiectasias, as well as arteriovenous malformations in the brain, spine, lungs, gastrointestinal tract, and liver. The AV malformations can progress to high output cardiac failure, which eventually may be irreversible. In the future, there may be effective non-transplant options, and if such agents become widely available, the recommendation to offer MELD score exception will need to be revisited.<sup>32,33</sup>

Documentation submitted for case review should include both of the following:

- Documentation of high output cardiac failure by echocardiography

---

<sup>30</sup>Porcel, J.M. "Identifying transudates misclassified by Light's criteria." *Current Opinion Pulmonary Medicine* 19 (2013): 362-7.

<sup>31</sup>Hewett, L.J., M.L. Bradshaw, L.L. Gordon, et al. "Diagnosis of isolated hepatic hydrothorax using peritoneal scintigraphy." *Hepatology* (2016).

<sup>32</sup>Lee, M., D.Y. Sze, C.A. Bonham, et al. "Hepatic arteriovenous malformations from hereditary hemorrhagic telangiectasia: treatment with liver transplantation." *Dig Dis Sci* 55 (2010): 3059-62.

<sup>33</sup>Boillot, O., F. Bianco, J.P. Viale, et al. "Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement." *Gastroenterology* 116 (1999): 187-92.

- Imaging supporting intra-hepatic AV malformations or severe diffuse bilobar hepatic necrosis in the setting of hepatic AV malformation

## Multiple Hepatic Adenomas

Hepatic adenomas (HA) are rare benign nodules occurring principally in women taking oral contraceptives, are solitary or multiple, and highly variable in size; there is no consensus for their management except that once their size exceeds 5 cm nodules are resected to prevent 2 major complications: bleeding and malignant transformation. An exception to this is in men where it is recommended to remove smaller nodules. The presence of HCC in HA is a well-documented observation, the risk ranging from 5 to 9%; gene coding for  $\beta$ -catenin mutations (15-18% of cases) are associated with a high risk of malignant transformation (together with cytologic atypia). HA are a frequent mode of presentation in some genetic diseases, particularly Glycogen Storage Disease (GSD) and congenital or acquired vascular anomalies.

**Orthotopic liver transplantation for HA remains an extremely rare indication; however, it is a valid therapeutic option in select patients with adenoma with risk of malignant transformation, not amenable to resection (the reason must be provided), and one or more of the following:**

- Malignant transformation proven by biopsy
- Presence of glycogen storage disease which increases the risk for malignant transformation

The identification of these criteria is mandatory to aid in the decision-making process.<sup>34,35,36,37</sup>

## Neuroendocrine Tumors (NET)

A review of the literature supports that candidates with NET are expected to have a low risk of waiting list drop-out.

**Transplant programs should be aware of the following criteria when submitting exceptions for NET. The Review Board should consider the following criteria when reviewing exception applications for candidates with NET.**

- Resection of primary malignancy and extra-hepatic disease without any evidence of recurrence at least six months prior to MELD exception request.
- Neuroendocrine Liver Metastasis (NLM) limited to the liver, Bi-lobar, not amenable to resection.

---

<sup>34</sup>Blanc, J.F., N. Frulio, L. Chiche, et al. "Hepatocellular adenoma management: call for shared guidelines and multidisciplinary approach." *Clinics and research in hepatology and gastroenterology* 39 (2015): 180-187.

<sup>35</sup>Chiche, L., A. David, R. Adam, et al. "Liver transplantation for adenomatosis: European experience." *Liver Transplantation* 22 (2016): 516-526.

<sup>36</sup>Alagusundaramoorthy, S. S., V. Vilchez, A. Zanni, et al. "Role of transplantation in the treatment of benign solid tumors of the liver: a review of the United Network of Organ Sharing data set." *JAMA Surgery* 150 (2015): 337-342.

<sup>37</sup>Dokmak, S., V. Paradis, V. Vilgrain, et al. "A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas." *Gastroenterology* 137 (2009): 1698-1705.

Tumors in the liver should meet the following radiographic characteristics on *either* CT or MRI:

1. If CT Scan:
    - a. Triple phase contrast Lesions may be seen on only one of the three phases
    - b. Arterial phase: may demonstrate a strong enhancement
    - c. Large lesions can become necrotic/calcified
  2. If MRI Appearance:
    - a. Liver metastasis are hypodense on T1 and hypervascular in T2 wave images
    - b. Diffusion restriction
    - c. Majority of lesions are hypervascular on arterial phase with wash –out during portal venous phase
    - d. Hepatobiliary phase post Gadoxetate Disodium (Eovist): Hypointense lesions are characteristics of NET
- 
1. Consider for exception only those with a NET of Gastro-entero-pancreatic (GEP) origin tumors with portal system drainage. Note: Neuroendocrine tumors with the primary located in the lower rectum, esophagus, lung, adrenal gland and thyroid are not candidates for automatic MELD exception.
  2. Lower - intermediate grade following the WHO classification. Only well differentiated (Low grade, G1) and moderately differentiated (intermediate grade G2). Mitotic rate <20 per 10 HPF with less than 20% ki 67 positive markers.
  3. Tumor metastatic replacement should not exceed 50% of the total liver volume.
  4. Negative metastatic workup should include one of the following:
    - a. Positron emission tomography (PET scan)
    - b. Somatostatin receptor scintigraphy
    - c. Gallium-68 (68Ga) labeled somatostatin analogue 1,4,7,10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA)-D-Phe1-Tyr3–octreotide (DOTATOC), or other scintigraphy to rule out extra-hepatic disease, especially bone metastasis.

**Note:** Exploratory laparotomy and or laparoscopy is not required prior to MELD exception request.

1. No evidence for extra-hepatic tumor recurrence based on metastatic radiologic workup at least 3 months prior to MELD exception request (submit date).
2. Recheck metastatic workup every 3 months for MELD exception increase consideration by the Review Board. Occurrence of extra-hepatic progression – for instance lymph-nodal Ga68 positive locations – should indicate de-listing. Patients may come back to the list if any extra-hepatic disease is zeroed and remained so for at least 6 months.
3. Presence of extra-hepatic solid organ metastases (i.e. lungs, bones) should be a permanent exclusion criteria

## Polycystic Liver Disease (PLD)

Patients with PLD who are not clinically eligible for resection/fenestration or alternative therapy may benefit from MELD exception points. Indication for an exception include those with PLD with severe symptoms related to PLD plus *any* of the following:

- Hepatic decompensation or severe portal hypertensive complications
- Concurrent hemodialysis
- GFR less than 20 ml/min
- Patient with a prior kidney transplant



- Moderate to severe protein calorie malnutrition as documented by a registered dietician using any of the following:
  - Modified Global Leadership Initiative on Malnutrition (GLIM) Phenotypic criteria
  - American Society for Enteral and Parenteral Nutrition (ASPEN) criteria
  - Nutrition Focused Physical Exam (NFPE)
  - Subjective Global Assessment (SGA-C score)
- Severe sarcopenia as documented with skeletal muscle index (SMI < 39 cm<sup>2</sup>/m<sup>2</sup> in women and < 50 cm<sup>2</sup>/m<sup>2</sup> in men)<sup>38</sup> or equivalent

Patients who meet the criteria above are eligible for a MELD exception equivalent to MMaT.

## Portopulmonary Hypertension

Candidates meeting the criteria in *Policy 9.5: Specific Standardized MELD or PELD Score Exceptions* are eligible for MELD or PELD score exceptions that do not require evaluation by the full Review Board.

## Primary Sclerosing Cholangitis or Secondary Sclerosing Cholangitis

Candidates with Primary Sclerosing Cholangitis (PSC) or Secondary Sclerosing Cholangitis (SSC) may be at risk of adverse outcomes secondary to sepsis from cholangitis, which may not be reflected in the candidate's calculated MELD score.

**Based on clinical experience and a review of the available literature, transplant programs should provide the following elements when submitting exceptions for PSC or SSC and the Review Board should consider the following elements when reviewing exception applications for candidates with PSC or SSC.**

The candidate must meet both of the following two criteria:

1. The candidate has been admitted to the hospital two or more times within a one year period with a documented blood stream infection or evidence of sepsis including hemodynamic instability requiring vasopressors
2. The candidate has cirrhosis

In addition the candidate must have one of the following criteria:

- The candidate has biliary tract stricture which are not responsive to treatment by interventional radiology (PTC) or therapeutic endoscopy (ERCP) or
- The candidate has been diagnosed with a highly-resistant infectious organism (e.g. Vancomycin Resistant Enterococcus (VRE), Extended Spectrum Beta-Lactamase (ESBL) producing gram negative organisms, Carbapenem-resistant Enterobacteriaceae (CRE), and Multidrug-resistant Acinetobacter.)

## Metabolic Disease

Adults who develop metabolic symptoms secondary to an inherited organic acidemia or urea cycle defect which are typically transplanted during infancy or childhood may be suitable for MELD exception.

---

<sup>38</sup> Carey, Elizabeth J., Jennifer C. Lai, Connie W. Wang, Srinivasan Dasarathy, Iryna Lobach, Aldo J. Montano-Loza, and Michael A. Dunn. "A Multicenter Study to Define Sarcopenia in Patients with End-Stage Liver Disease." *Liver Transplantation* 23, no. 5 (2017): 625–33. <https://doi.org/10.1002/lt.24750>.

Given later onset, anticipate a reduced urgency compared to early-onset disease, thus priority for transplant may be similar to other exceptions, though if a patient has more urgent medical condition, as reflected by life-threatening complications, a higher priority score can be considered.

## Post-Transplant Complications

### Small for Size Syndrome

Small for size syndrome refers to graft dysfunction of varying severity occurring in the early post-operative period, less than 30 days, following transplantation of a size-reduced liver allograft, with no other identified cause of graft dysfunction such as vascular thrombosis, prolonged ischemia, or other etiology.<sup>39</sup> Typical findings include worsening cholestasis and ascites. With optimal care, some patients may recover while others may require re-transplantation.

**In many cases, the calculated MELD score will provide adequate priority. However, mortality risk may not be adequately reflected by the calculated MELD score in cases of severe dysfunction, and an exception may be appropriate.**

Documentation submitted for case review should include all of the following:

- Risk factor for small for size syndrome
- Interventions used to treat small for size syndrome
- Clinical status of the patient (hospitalized, requiring ICU care, intubated)

### Chronic Rejection

**There is inadequate evidence to support granting a MELD exception for chronic rejection in adult candidates with the typical clinical symptoms associated with this diagnosis.**

In cases where re-transplantation is being considered, it is anticipated that progressive injury of the allograft due to rejection will be reflected in the development of liver dysfunction, and prioritization by MELD score may be appropriate. Cases with atypical clinical scenarios in which the degree of liver dysfunction and risk of waitlist mortality are not reflected by the MELD score may be considered on an individual basis.

### Diffuse Ischemic Cholangiopathy

Diffuse ischemic cholangiopathy is a complication associated with donation after circulatory death (DCD) donors. Analysis of waitlist outcomes for patients re-listed after undergoing liver transplant from a DCD donor demonstrates that these patients have a similar or improved waitlist survival compared to donation after brain death (DBD) candidates who are re-listed with similar MELD scores.<sup>40</sup> However, patients with ischemic cholangiopathy may have significant morbidity and require multiple repeat biliary interventions and repeat hospitalizations for cholangitis. Despite similar waitlist outcomes as DBD donor liver recipients who are listed for retransplant, the Committee supports increased priority for prior DCD donor liver recipients to encourage use of DCD livers when appropriate.

---

<sup>39</sup>Uemura, T., S. Wada, T. Kaido, et al. "How far can we lower graft-to-recipient weight ratio for living donor liver transplantation under modulation of portal venous pressure?" *Surgery* 159 (2016): 1623-30.

<sup>40</sup>Allen, A.M., W.R. Kim, H. Xiong, et al "Survival of recipients of livers from donation after circulatory death who are relisted and undergo retransplant for graft failure." *Am J Transplant* 15 (2014): 1120-8.

In addition, analyses has shown that patients with a prior DCD transplant and an approved MELD score exception had an improved survival compared to those who never had an exception approved.<sup>41</sup> Patients with biliary injuries and need for biliary interventions also have been demonstrated to have an increased risk of graft loss and death.<sup>42</sup> **Therefore, patients with a prior DCD transplant who demonstrated two or more of the following criteria within 12 months of transplant are eligible for MELD exception equivalent to MMaT:**

- Persistent cholestasis as defined by abnormal bilirubin (greater than 2 mg/dl)
- Two or more episodes of cholangitis with an associated bacteremia requiring hospital admission
- Evidence of non-anastomotic biliary strictures not responsive to further treatment

### Late Vascular Complications

Patients with hepatic artery thrombosis occurring within 7 days of transplant with associated severe graft dysfunction may be eligible for Status 1A, or occurring within 14 days of transplantation without severe graft dysfunction may be eligible for a standard exception of 40.<sup>43,44</sup> Cases of late hepatic artery thrombosis which do not meet these criteria are not eligible for standard MELD exception. **Due to the highly variable outcomes associated with late hepatic artery thrombosis, there is inadequate evidence to support granting a MELD exception in adult candidates with the typical clinical symptoms, including hepatic abscess and intrahepatic biliary strictures that may be associated with late HAT. However, patients with atypical severe complications may be considered for MELD exception on an individual basis.** Complications that warrant consideration of MELD exception are similar to those criteria noted for DCD cholangiopathy (with 2 or more episodes of cholangitis requiring hospital admission over a 3 months period plus biliary strictures not responsive to further treatment or bacteremia with highly resistant organisms). Patients with early HAT just beyond 7 or 14 day cut off with evidence of severe graft dysfunction may be considered for MELD exception, depending on the clinical scenario.

### Pruritus

**There is inadequate evidence to support granting a MELD exception for pruritus in adult candidates with the typical clinical symptoms associated with this diagnosis.** Pruritus is a manifestation of predominantly cholestatic liver diseases. It had been reported that chronic pruritus may lead to a decreased quality of life, prolonged wound healing, skin infections, and sleep disturbance.<sup>45</sup> The frequency ranges from 80-100% for patients suffering from Primary Biliary Cirrhosis; 20-40% for patients with primary Sclerosing Cholangitis and Chronic Viral Hepatitis among other diseases.<sup>46</sup> The pruritus increases as the disease is progresses. So far data have failed to support an endpoint related to quantity but rather of quality of life and were considered inappropriate for additional MELD points.<sup>47</sup> Due to inadequate evidence of increased risk of pre-transplant mortality, or a widely-accepted threshold for access to liver transplant, MELD score exception for isolated clinical finding of pruritus is not

---

<sup>41</sup>Makuda, R.C., P.L. Abt, D.S. Goldberg. "Use of Model for End-Stage Liver Disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation." *Liver Transpl* 21 (2015):554-60.

<sup>42</sup>Axelrod, D.A., K.L. Lentine, H. Xiao, et al. "National assessment of early biliary complications following liver transplantation: incidence and outcomes." *Liver Transpl.* 20 (2014): 446-56.

<sup>43</sup>Policy 9.1.A: Adult Status 1A Requirements, Organ Procurement and Transplantation Network Policies.

<sup>44</sup>Policy 9.3.C: Specific MELD/PELD Exceptions, Organ Procurement and Transplantation Network Policies.

<sup>45</sup>Pruritus in chronic cholestatic liver disease. Bunchorntavakul C, Reddy KR *Clin Liver Dis.* 2012 May;16(2):331-46.

<sup>46</sup>Elman, S., L.S. Hynan, V. Gabriel, et al. "The 5-D itch scale: a new measure of pruritus." *Br J Dermatol* 162 (2010): 587-93

<sup>47</sup>Martin, P., A. DiMartini, S. Feng, et al. "Evaluation for liver transplantation in adults: 2013 practice guideline by the AASLD and the American Society of Transplantation." (2013): 61.

recommended.

## Conclusion

Review Board members should consult this resource when assessing adult MELD exception requests. Liver programs should also consider this guidance when submitting exception requests for adult candidates with these diagnoses. However, these guidelines are not prescriptive of clinical practice.